<p><a href="https://blog.naver.com/jopd64/223651014737" target="_blank" class="ke-link">https://blog.naver.com/jopd64/223651014737</a></p><div class="figure-open" contenteditable="false" data-ke-type="opengraph" data-ke-align="alignCenter" data-og-type="website" data-og-title="혈액암 치료 새 물결 이중항체 신약…글로벌 시장 연착륙" data-og-description="혈액암에서 주목받는 이중항체 신약이 글로벌에서 높은 성장세를 기록 중이다. 이중항체 신약은 서로 다른 ..." data-og-host="blog.naver.com" data-og-source-url="https://blog.naver.com/jopd64/223651014737" data-og-url="https://blog.naver.com/jopd64/223651014737" data-og-image="https://scrap.kakaocdn.net/dn/LYPuc/hyXwuJTY96/CEnkfgoHfRWXTHY8ZPG82k/img.png?width=270&height=270&face=0_0_270_270"><a href="https://blog.naver.com/jopd64/223651014737" target="_blank" data-source-url="https://blog.naver.com/jopd64/223651014737"><div class="og-image"><img src="https://scrap.kakaocdn.net/dn/LYPuc/hyXwuJTY96/CEnkfgoHfRWXTHY8ZPG82k/img.png?width=270&height=270&face=0_0_270_270" alt="" xxonerror="this.src="//img1.kakaocdn.net/thumb/C200x200/?fname=https%3A%2F%2Ft1.daumcdn.net%2Fcafe_image%2Fcafe_meta_image_190529.png""></div><div class="og-text"><p class="og-title">혈액암 치료 새 물결 이중항체 신약…글로벌 시장 연착륙</p><p class="og-desc">혈액암에서 주목받는 이중항체 신약이 글로벌에서 높은 성장세를 기록 중이다. 이중항체 신약은 서로 다른 ...</p><p class="og-host">blog.naver.com</p></div></a></div><p><a href="https://www.sisajournal-e.com/news/articleView.html?idxno=402813" target="_blank" class="ke-link">https://www.sisajournal-e.com/news/articleView.html?idxno=402813</a></p><div class="figure-open" contenteditable="false" data-ke-type="opengraph" data-ke-align="alignCenter" data-og-type="website" data-og-title="신라젠, ‘혈액암 신약’ 도전···적응증 넓혀 새 기회 모색 - 시사저널e" data-og-description="[시사저널e=최다은 기자] 신라젠이 자체 항암 신약 파이프라인 적응증을 확장해 가치 제고에 나선다. 연구개발(R&D) 범위가 항암 바이러스 치료제 후보물질 ‘펙사" data-og-host="www.sisajournal-e.com" data-og-source-url="https://www.sisajournal-e.com/news/articleView.html?idxno=402813" data-og-url="https://www.sisajournal-e.com/news/articleView.html?idxno=402813" data-og-image="https://scrap.kakaocdn.net/dn/fQHDw/hyXzHgLyfj/kXCdRqekI3hoYJBCLzFdy1/img.jpg?width=860&height=493&face=0_0_860_493,https://scrap.kakaocdn.net/dn/PitlI/hyXzVlKpp0/ZkYwUwzy7sLHw45XVHkmdK/img.jpg?width=860&height=493&face=0_0_860_493"><a href="https://www.sisajournal-e.com/news/articleView.html?idxno=402813" target="_blank" data-source-url="https://www.sisajournal-e.com/news/articleView.html?idxno=402813"><div class="og-image"><img src="https://scrap.kakaocdn.net/dn/fQHDw/hyXzHgLyfj/kXCdRqekI3hoYJBCLzFdy1/img.jpg?width=860&height=493&face=0_0_860_493,https://scrap.kakaocdn.net/dn/PitlI/hyXzVlKpp0/ZkYwUwzy7sLHw45XVHkmdK/img.jpg?width=860&height=493&face=0_0_860_493" alt="" xxonerror="this.src="//img1.kakaocdn.net/thumb/C200x200/?fname=https%3A%2F%2Ft1.daumcdn.net%2Fcafe_image%2Fcafe_meta_image_190529.png""></div><div class="og-text"><p class="og-title">신라젠, ‘혈액암 신약’ 도전···적응증 넓혀 새 기회 모색 - 시사저널e</p><p class="og-desc">[시사저널e=최다은 기자] 신라젠이 자체 항암 신약 파이프라인 적응증을 확장해 가치 제고에 나선다. 연구개발(R&D) 범위가 항암 바이러스 치료제 후보물질 ‘펙사</p><p class="og-host">www.sisajournal-e.com</p></div></a></div><p><a href="https://blog.naver.com/gas0424/223311600339" target="_blank" class="ke-link">https://blog.naver.com/gas0424/223311600339</a></p><div class="figure-open" contenteditable="false" data-ke-type="opengraph" data-ke-align="alignCenter" data-og-type="website" data-og-title="혈액암 신약 '보술리프', 국내 '허가 적응증'과 '급여 기준' 너무 달라" data-og-description="혈액암 신약 '보술리프', 국내 '허가 적응증'과 '급여 기준' 너무 달라 - 2..." data-og-host="blog.naver.com" data-og-source-url="https://blog.naver.com/gas0424/223311600339" data-og-url="https://blog.naver.com/gas0424/223311600339" data-og-image="https://scrap.kakaocdn.net/dn/bnHwrL/hyXwtxHcLN/6Dv1vfC8KCw1yzQEoV8YbK/img.png?width=270&height=270&face=0_0_270_270"><a href="https://blog.naver.com/gas0424/223311600339" target="_blank" data-source-url="https://blog.naver.com/gas0424/223311600339"><div class="og-image"><img src="https://scrap.kakaocdn.net/dn/bnHwrL/hyXwtxHcLN/6Dv1vfC8KCw1yzQEoV8YbK/img.png?width=270&height=270&face=0_0_270_270" alt="" xxonerror="this.src="//img1.kakaocdn.net/thumb/C200x200/?fname=https%3A%2F%2Ft1.daumcdn.net%2Fcafe_image%2Fcafe_meta_image_190529.png""></div><div class="og-text"><p class="og-title">혈액암 신약 '보술리프', 국내 '허가 적응증'과 '급여 기준' 너무 달라</p><p class="og-desc">혈액암 신약 '보술리프', 국내 '허가 적응증'과 '급여 기준' 너무 달라 - 2...</p><p class="og-host">blog.naver.com</p></div></a></div><p><a href="https://www.kukinews.com/article/view/kuk202411150179" target="_blank" class="ke-link">https://www.kukinews.com/article/view/kuk202411150179</a></p><div class="figure-open" contenteditable="false" data-ke-type="opengraph" data-ke-align="alignCenter" data-og-type="website" data-og-title="초기치료 중요한 혈액암…“신약 급여 절실”" data-og-description="전이나 악화 속도가 빠른 혈액암은 처음 진단받은 시기, 또 첫 재발 시점에서 적정 치료를 받는 게 매우 중요한데, 국내에선 신약이 도입되고 급여가" data-og-host="www.kukinews.com" data-og-source-url="https://www.kukinews.com/article/view/kuk202411150179" data-og-url="https://www.kukinews.com/article/view/kuk202411150179" data-og-image="https://scrap.kakaocdn.net/dn/bKzp3K/hyXzTVMFRM/NEjdkQNBQqxNMkYq7OaCf0/img.jpg?width=1920&height=1280&face=0_0_1920_1280,https://scrap.kakaocdn.net/dn/bqYC7o/hyXzIzYsRg/y8vJIOWkFo5MfxDC2SkTE0/img.jpg?width=144&height=144&face=0_0_144_144,https://scrap.kakaocdn.net/dn/6JrWZ/hyXwowbnVK/b4AkkttVdDpwGI37KaFa11/img.jpg?width=800&height=533&face=0_0_800_533"><a href="https://www.kukinews.com/article/view/kuk202411150179" target="_blank" data-source-url="https://www.kukinews.com/article/view/kuk202411150179"><div class="og-image"><img src="https://scrap.kakaocdn.net/dn/bKzp3K/hyXzTVMFRM/NEjdkQNBQqxNMkYq7OaCf0/img.jpg?width=1920&height=1280&face=0_0_1920_1280,https://scrap.kakaocdn.net/dn/bqYC7o/hyXzIzYsRg/y8vJIOWkFo5MfxDC2SkTE0/img.jpg?width=144&height=144&face=0_0_144_144,https://scrap.kakaocdn.net/dn/6JrWZ/hyXwowbnVK/b4AkkttVdDpwGI37KaFa11/img.jpg?width=800&height=533&face=0_0_800_533" alt="" xxonerror="this.src="//img1.kakaocdn.net/thumb/C200x200/?fname=https%3A%2F%2Ft1.daumcdn.net%2Fcafe_image%2Fcafe_meta_image_190529.png""></div><div class="og-text"><p class="og-title">초기치료 중요한 혈액암…“신약 급여 절실”</p><p class="og-desc">전이나 악화 속도가 빠른 혈액암은 처음 진단받은 시기, 또 첫 재발 시점에서 적정 치료를 받는 게 매우 중요한데, 국내에선 신약이 도입되고 급여가</p><p class="og-host">www.kukinews.com</p></div></a></div><p> </p>
<!-- -->
